MedTrace Logo

Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

NCT03193502 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-10-13

No results posted yet for this study

Summary

-Rivaroxaban is factor Xa inhibitor

Conditions

  • Portal Vein Thrombosis

Interventions

DRUG

rivaroxaban

rivaroxaban

Sponsors & Collaborators

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Amr Hanafy, Professor · Hepatology unit - Zagazig University

  • Mohamed Basha, Consultant · Radiology Dept - Zagazig University

  • Sherief Abd-elsalam, consultant · Hepatology - Gastroenterology - Tanta University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-01
Primary Completion
2020-07-31
Completion
2020-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03193502 on ClinicalTrials.gov